GlassScriptPhysician profile
Ray T Douglas
NPI 1184643488
$3,616.67
in general payments reported to CMS, 2019-2025
20 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $157 · 2021: $309 · 2022: $559 · 2023: $839 · 2024: $583 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.89 | 2023-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $634.00 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $403.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $376.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $262.66 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.75 | 2019-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $212.43 | 2019-2025 | |
| Amgen INC. | $189.27 | 2019-2025 | Tepezza, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $188.28 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $105.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.78 | 2019-2025 | Gardasil 9, Vaxelis, Proquad |
| E.R. Squibb & Sons, L.L.C. | $42.04 | 2019-2023 | Camzyos, Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $36.17 | 2022 | |
| Sanofi Pasteur INC. | $34.30 | 2019-2020 | |
| Dexcom, INC. | $22.05 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.43 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.95 | 2024 | Voquezna |
| Philips North America LLC | $15.69 | 2022 | |
| Corcept Therapeutics | $15.27 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.